<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452008</url>
  </required_header>
  <id_info>
    <org_study_id>J1557</org_study_id>
    <secondary_id>IRB00065746</secondary_id>
    <nct_id>NCT02452008</nct_id>
  </id_info>
  <brief_title>Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the progression free survival (PFS) of
      patients with metastatic castration-resistant prostate cancer treated with enzalutamide in
      combination with LY2157299 (Arm 1) versus enzalutamide alone (Arm 2).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299 (Arm 1) versus enzalutamide alone (Arm 2) using RECIST 1.1 criteria.</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor marker kinetics (PSA) in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299 (Arm 1) versus enzalutamide alone (Arm 2).</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299 (Arm 1) versus enzalutamide alone (Arm 2).</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients experiencing treatment-related toxicities</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: Enzalutamide with LY2157299</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Enzalutamide alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.</description>
    <arm_group_label>Arm 1: Enzalutamide with LY2157299</arm_group_label>
    <arm_group_label>Arm 2: Enzalutamide alone</arm_group_label>
    <other_name>XTANDI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2157299</intervention_name>
    <description>150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.</description>
    <arm_group_label>Arm 1: Enzalutamide with LY2157299</arm_group_label>
    <other_name>TGF-β receptor inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have metastatic castration-resistant prostate cancer

          -  Must have had prior abiraterone treatment

          -  Life expectancy of greater than 3 months

          -  ECOG performance status 0 or 2

          -  Age ≥18 years

          -  Have measurable disease

          -  Patients acceptance to have a tumor biopsy of an accessible lesion at baseline and on
             treatment if the lesion can be biopsied with acceptable clinical risk (as judged by
             the investigator).

          -  Ability to take oral medication

          -  Patients must have adequate organ and marrow function defined by study-specified
             laboratory tests

          -  Must use acceptable form of birth control while on study

          -  Ability to understand and willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Known history or evidence of brain metastases

          -  Prior chemotherapy for metastatic disease in castration-resistant prostate cancer

          -  Had surgery within 4 weeks prior to the first dose of study drug

          -  Had radiation, biological, or other investigational cancer therapy within 2 weeks
             prior to the first dose of study drug

          -  Had second-line hormonal therapy within 2 weeks prior to the first dose of study drug

          -  Systemic steroids within 1 weeks prior to the first dose of study drug

          -  Had prior enzalutamide, ARN-509, or galeterone therapy

          -  Have moderate or severe cardiovascular disease

          -  Have a history of a seizure

          -  Have uncontrolled intercurrent illness, including but not limited to ongoing or active
             infection, systematic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia or psychiatric condition that would limit compliance with study
             requirements

          -  Have a history of any autoimmune disease:inflammatory bowel disease, (including
             ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive
             sclerosis (scleroderma), systemic lupus erythmatosus (SLE) autoimmune vasculitis
             (e.g., Wegener's Granulomatosis), CNS or motor neuropathy considered to be of
             autoimmune origin (e.g., Guillian-Barre Syndrome, Myasthenia Gravis, Multiple
             Sclerosis)

          -  Have known history of infection with HIV, hepatitis B, or hepatitis C
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Irina Rifkind, RN</last_name>
    <phone>410-502-2043</phone>
    <email>irifkin1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Channing Paller, MD</last_name>
    <phone>410-955-8239</phone>
    <email>cpaller1@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sibley Memorial Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Powers, RN</last_name>
      <phone>202-660-5772</phone>
      <email>jpower22@JHMI.EDU</email>
    </contact>
    <investigator>
      <last_name>Channing Paller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maha Hussain, MD</last_name>
      <phone>312-908-5487</phone>
      <email>maha.hussain@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Maha Hussain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Russel Szmulewitz, MD</last_name>
      <phone>773-702-7609</phone>
      <email>rszmulew@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kelly O'Connor</last_name>
      <phone>773-702-4653</phone>
      <email>koconnor@medicine.bsd.uchicago.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Russel Szmulewitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Channing Paller, MD</last_name>
      <phone>410-614-6321</phone>
      <email>cpaller@JHMI.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Irina Rifkind, RN</last_name>
      <phone>410-502-2043</phone>
      <email>irifkin1@JHMI.EDU</email>
    </contact_backup>
    <investigator>
      <last_name>Channing Paller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic castration-resistant prostate cancer</keyword>
  <keyword>enzalutamide</keyword>
  <keyword>LY2157299</keyword>
  <keyword>TGF-β receptor inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

